The question is usually presented as a challenge:
If vaccines are so safe, why does Big Pharma need immunity from lawsuits?
Attorney Aaron Siri has made versions of this question a part of his criticisms of vaccine policy. While Siri does not necessarily require an answer to the question of the legislative history of the vaccines, he does raise an important point regarding the safety of those vaccines.
If vaccines are considered to be safe by their manufacturers and by public health officials, then why do manufacturers receive such broad protections against lawsuits related to those products?
The question shifts the focus of the discussion from the potential dangers of specific vaccines to the reasons for which the vaccine manufacturers were given such protections in the first place. Also, the answer to this question would show a lack of confidence of those vaccine manufacturers in the safety of their products.
That implication is worth examining, but the question does not answer itself.
Congress granted those protections because safe does not mean risk-free, and lawmakers decided that the public interest in maintaining a stable vaccine supply justified protecting manufacturers from much of the cost and uncertainty of ordinary product-liability litigation.
In 1986, Congress created the National Vaccine Injury Compensation Program, or VICP. People who believe they were injured by certain vaccines generally must go through that program before pursuing a lawsuit against the manufacturer or administrator. In exchange for the right to manufacture pharmaceutical products, these manufacturers received important protection from civil liability in relation to the drugs that they manufactured.
That is the trade. The government accepted that serious vaccine injuries can happen, created a system to compensate those people, and restricted the circumstances under which manufacturers can be sued.
Although the existence of these protections does not prove the vaccines are unsafe, it is not meaningless. It is instead a decision made by the government to shift the risk of financial losses from the vaccine manufacturers to the Compensation Program for the Vaccination Program.
The protection is broad, but it is not absolute
“Big Pharma” is the language of the challenge. The law is more specific. It protects manufacturers and administrators of vaccines covered by the VICP. It does not give every pharmaceutical company blanket immunity for every product it sells.
Under the National Childhood Vaccine Injury Act, someone seeking more than $1,000 for an alleged injury from a covered vaccine generally must file a VICP petition first.
In some circumstances, a petitioner who rejects the program’s judgment or withdraws after the program fails to meet certain deadlines may pursue a civil lawsuit. HRSA acknowledges that the liability protections are not absolute.
Still, the protection is substantial.
In 2011, the Supreme Court ruled in Bruesewitz v. Wyeth that the Vaccine Act preempts all design-defect claims against manufacturers involving injuries caused by the side effects of covered vaccines. A claimant cannot leave the VICP and sue on the theory that the vaccine should have been designed differently.
The Supreme Court described the arrangement as a tradeoff. Manufacturers received significant protection from tort liability, while people alleging injury were given access to a no-fault compensation program funded through an excise tax on covered vaccines.
Manufacturers may still face certain claims involving manufacturing defects, failures to comply with federal requirements, or conduct falling outside the Act’s protections. Claimants must first follow the VICP process when the law requires it.
“Immunity” is therefore convenient shorthand, but broad liability protection is more precise when discussing routinely administered vaccines. Lawsuits remain possible in limited circumstances, but many claims normally available against other product manufacturers are restricted or barred.
Why did Congress create this protection?
According to HRSA’s history of the VICP, lawsuits against vaccine manufacturers and healthcare providers were threatening to cause vaccine shortages, raise costs, and reduce vaccination rates.
Congress responded by creating a system intended to maintain an adequate vaccine supply, stabilize vaccine costs, and provide injured people with a less costly alternative to traditional litigation.
That was a policy decision, not a scientific finding that vaccines were perfectly safe.
Even a product with a low rate of serious injury can generate substantial litigation when it is given to millions of people. Some claims will involve recognized adverse reactions. Others will involve medical problems that happened after vaccination but were not caused by it. Sorting those cases through ordinary courts can be slow and expensive.
Congress decided that a specialized compensation system was preferable.
Whether it struck the right balance is a separate question.
What about the billions already paid?
The government has paid billions through the vaccine compensation system. That fact matters, but it does not tell us how frequently vaccines cause serious injuries or mean that every compensated claim established causation.
I examined the payout total, settlements, legal fees, and missing denominator separately in Billions Paid for Vaccine Injuries?
Here, the relevant point is that the compensation program and manufacturer liability protections were created together. Congress restricted many lawsuits against manufacturers while establishing a separate system to pay people with qualifying claims.
Who actually pays?
VICP awards are paid from the Vaccine Injury Compensation Trust Fund.
The fund receives revenue from a federal excise tax on covered vaccines. The tax is 75 cents for each disease a dose prevents. A measles, mumps, and rubella vaccine is taxed at $2.25 because it prevents three diseases.
An injured person is therefore generally compensated by the trust fund rather than through a judgment paid directly by the vaccine manufacturer.
That distinction matters. The financial consequences of an injury are spread through a government-administered fund tied to vaccine sales instead of being placed entirely on the company that made the individual product.
That does not prove the arrangement is improper. It does show that the risk has been redistributed.
COVID vaccines are covered by a different law
If the immunity question is specifically about COVID vaccines, the legal framework is different.
COVID vaccine claims are handled through the Countermeasures Injury Compensation Program, or CICP, rather than the VICP.
The Public Readiness and Emergency Preparedness Act provides immunity from suit and liability to covered people and organizations involved in developing, manufacturing, testing, distributing, administering, and using designated emergency countermeasures.
The principal statutory exception is willful misconduct.
That protection is not unique to COVID vaccines. The PREP Act can cover vaccines, drugs, medical devices, and other countermeasures used in response to specified public-health threats.
Still, it is a very different legal route from an ordinary product-liability lawsuit. Someone alleging a serious COVID vaccine injury must seek benefits through the CICP and meet that program’s requirements.
The VICP and CICP should not be treated as the same system simply because both can involve vaccines.
Are we leaning too far toward the government’s explanation by describing immunity as a reasonable policy tradeoff?
Possibly.
Liability does more than compensate an injured person. Lawsuits can expose internal records, challenge decisions made by manufacturers, and create financial pressure to improve a product. When design-defect claims are barred, more responsibility falls on regulators, postmarketing surveillance, independent researchers, and the compensation system itself.
That makes transparency and effective safety monitoring especially important.
It is also fair to ask whether injured people receive the other half of the bargain Congress promised. Is the process accessible? Are the filing deadlines reasonable? Are cases resolved quickly enough? Is compensation adequate? Are claimants given a meaningful opportunity to prove causation?
HRSA’s August 2026 report says VICP petitions take an average of two to three years to adjudicate. COVID claims face a separate program with different requirements and limitations.
But we should question the other direction too.
Siri’s question implies that a genuinely safe product would never need liability protection. That does not necessarily follow. A product used hundreds of millions of times can generate enormous litigation costs even if serious injuries are rare. The existence of protection proves that Congress was concerned about litigation and vaccine supply. It does not prove that manufacturers secretly knew their vaccines were broadly dangerous.
A policy can have a legitimate purpose and still deserve scrutiny decades later.
So why does the industry need immunity?
Because Congress believed unrestricted vaccine litigation could threaten vaccine availability and raise costs. It chose to protect manufacturers while moving injury claims into a government-administered compensation program.
That answers why the protection exists.
What the protection does not prove is that vaccines are broadly dangerous. What it does prove is that lawmakers recognized the possibility of serious injury and decided that manufacturers should not bear the same legal exposure they face with most other products.
Immunity is not a scientific verdict about vaccine safety. It is a legal and economic policy choice.
The real debate is whether that choice still gives injured people a fair deal while protecting the vaccine supply, or whether the balance has shifted too far toward the companies being protected.
Support independent, evidence-based analysis
If you value articles that take difficult questions seriously, examine the evidence, and question their own conclusions, consider subscribing to A Mind Less Wasted.
Free subscribers receive new articles as they are published. Paid subscriptions help support the research, source review, and time required to produce this work.
Subscribe for free, or become a paid supporter to help keep this work going
Resources
HRSA: About the National Vaccine Injury Compensation Program
HRSA: Vaccine liability protections and frequently asked questions
Siri & Glimstad: Can You Sue a Vaccine Manufacturer for a Vaccine Injury?